Why the study?
Does enoxaparin dose <0.95 mg/kg prevent supratherapeutic anti-Xa levels in hospitalized patients with morbid obesity compared to doses ≥0.95 mg/kg?
Does enoxaparin dose <0.95 mg/kg prevent supratherapeutic anti-Xa levels in hospitalized patients with morbid obesity compared to doses ≥0.95 mg/kg?
In hospitalized patients with morbid obesity, enoxaparin doses lower than the standard 1 mg/kg are more likely to achieve therapeutic anti-Xa levels without increasing subtherapeutic levels or bleeding.
Answers are grounded in this paper and cite their sources.
Lower enoxaparin doses associated with fewer supratherapeutic anti-Xa levels in morbid obesity; hypothesis-generating and should not change practice without RCTs.
BACKGROUND: The pharmacokinetic properties of enoxaparin may lead to supratherapeutic antifactor Xa (anti-Xa) levels and increased bleeding when standard treatment doses are used in patients with morbid obesity. OBJECTIVE: To evaluate the dose of enoxaparin needed to achieve therapeutic anti-Xa levels in a prospective, masked observational cohort of heterogeneous inpatients with morbid obesity and to determine whether patients with morbid obesity treated with 1 mg/kg of enoxaparin are at increased risk of supratherapeutic levels and bleeding events compared to patients receiving lower doses. METHODS: Hospitalized patients with a body mass index ≥40 kg/m(2) or actual body weight ≥140 kg and prescribed treatment doses of enoxaparin >60 mg per day were enrolled and consented to phlebotomy for determination of anti-Xa levels. RESULTS: Forty-one patients were included for data analysis. The dose of enoxaparin that resulted in therapeutic and supratherapeutic anti-Xa levels at steady state was 0.83 mg/kg and 0.98 mg/kg (-0.11; 95% confidence interval [CI] -0.20 to -0.01, P = .02), respectively. Enoxaparin dose as mg/kg of actual body weight was an independent predictor of having a supratherapeutic anti-Xa level. Patients with doses <0.95 mg/kg versus ≥0.95 mg/kg were less likely to have supratherapeutic levels (odds ratio 0.21 [95% CI 0.05-0.84], P = .02) and had similar rates of subtherapeutic levels. Doses <0.95 mg/kg and ≥0.95 mg/kg resulted in similar bleeding rates of 17.9% and 22.2% (P = .71), respectively. CONCLUSION: Patients with morbid obesity required less than the recommended 1 mg/kg enoxaparin dose to achieve therapeutic peak anti-Xa levels; therefore, initiation with lower dosages is prudent and anti-Xa monitoring should guide dosage adjustments.
No takes yet. Share an insight, caveat, or question.
Thompson‐Moore et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: